Redx Pharma plc Share Purchases by Directors (6582J)

TIDMREDX

RNS Number : 6582J

Redx Pharma plc

23 December 2020

REDX PHARMA PLC

("Redx" or "the Company")

Share Purchases by Directors

Alderley Park, 23 December 2020 - Redx Pharma (AIM:REDX), the drug discovery and development Group focused on cancer and fibrosis, announces that it has been notified that Lisa Anson, Chief Executive Officer, has on Tuesday 22 December acquired 39,998 Redx ordinary shares at the following prices:

 
 Number of Ordinary shares purchased   Price per share (pence) 
 39,998                                50p 
                                      ------------------------ 
 

Following this, Mrs Anson will hold 129,284 ordinary shares in the Company, representing 0.05 per cent. of the issued share capital.

-Ends-

For further information, please contact:

 
Redx Pharma Plc                              T: [phone] 
                                              918 
Lisa Anson, Chief Executive Officer 
 James Mead, Chief Financial Officer 
 
SPARK Advisory Partners (Nominated Advisor)   T: [phone] 
                                               3550 
Matt Davis/ Adam Dawes 
 
WG Partners LLP (Broker)                     T: [phone] 
                                              9330 
Claes Spång/ Chris Lee/ David Wilson 
 
 
FTI Consulting                               T: [phone] 
                                              1000 
Simon Conway/Ciara Martin 
 

About Redx Pharma Plc

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
----  ----------------------------------------------------------------------- 
 a.    Name                               Lisa Anson 
                                         ------------------------------------ 
 2     Reason for notification 
      ---------------------------------  ------------------------------------ 
 a.    Position/Status                    Chief Executive 
      ---------------------------------  ------------------------------------ 
 b.    Initial notification/              Initial Notification 
        Amendment 
      ---------------------------------  ------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------- 
 a.    Name                               Redx Pharma Plc 
      --------------------------------- 
 b.    LEI                                213800HMS4EBXO589Y37 
      ---------------------------------  ------------------------------------ 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  ----------------------------------------------------------------------- 
 a.    Description of                     Ordinary Shares of 1p each 
        the financial 
        instrument, type 
        of instrument 
                                           ISIN: GB00BSNB6S51 
        Identification 
        Code 
      ---------------------------------  ------------------------------------ 
 b.    Nature of the                      Purchase 
        transaction 
      ---------------------------------  ------------------------------------ 
 c.    Price(s) and volume(s)             39,998 at 50 pence per share 
      ---------------------------------  ------------------------------------ 
 d.    Aggregated information             39,998 at 50 pence per share 
        - Aggregated Volume 
        - Price 
      ---------------------------------  ------------------------------------ 
 e.    Date of the transaction            22/12/20 
      ---------------------------------  ------------------------------------ 
 f.    Place of the transaction           Outside of trading venue 
      ---------------------------------  ------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFIFVTFVLVFII

(END) Dow Jones Newswires

December 23, 2020 04:00 ET (09:00 GMT)